Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11331397 | 0.75 | LTA4H (0.49) | LTA4HCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1985113 | 0.75 | KDM1A (0.30) | — | |
| SCHEMBL11673331 | 0.75 | ALDH1A1 (0.46) | LMNA | |
| SCHEMBL11459021 | 0.72 | OPRK1 (0.54) | LTA4HL3MBTL1LMNAOPRK1PPARG | |
| SCHEMBL4367709 | 0.72 | — | — | |
| SCHEMBL10607135 | 0.71 | LTA4H (0.67) | LTA4HCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL16770891 | 0.71 | SLC6A4 (0.58) | LTA4HCALM1SLC6A4 | |
| SCHEMBL122993 | 0.70 | LTA4H (0.53) | LTA4HCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL11335723 | 0.70 | LTA4H (0.46) | LTA4HCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL10971437 | 0.69 | APP (0.51) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424500-A1 | LIPID FORMULATION OF APOPTOSIS PROMOTER | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010127198-A1 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127192-A1 | LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
| EP-2038252-A2 | SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF | University of Tennessee Research Foundation (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008008433-A2 | SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2008-01-17 | — | — | WO | disclosed |
| EP-1539123-A1 | USE OF A COMBINATION OF DPPE WITH OTHER CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF BREAST CANCER | The University of Manitoba (CA) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024131-A1 | USE OF A COMBINATION OF DPPE WITH OTHER CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF BREAST CANCER | THE UNIVERSITY OF MANITOBA (CA) | 2004-03-25 | — | — | WO | disclosed |
| EP-0737067-A1 | METHOD OF TREATMENT OF HORMONE-UNRESPONSIVE METASTATIC PROSTATE CANCER | UNIVERSITY OF MANITOBA (CA) | 1996-10-16 | — | — | EP | disclosed |
| EP-0684817-A1 | CANCER TREATMENT | UNIVERSITY OF MANITOBA (CA) | 1995-12-06 | — | — | EP | disclosed |
| WO-1995017887-A1 | METHOD OF TREATMENT OF HORMONE-UNRESPONSIVE METASTATIC PROSTATE CANCER | UNIVERSITY OF MANITOBA (CA) | 1995-07-06 | — | — | WO | disclosed |
| WO-1994018961-A1 | CANCER TREATMENT | UNIVERSITY OF MANITOBA (CA) | 1994-09-01 | — | — | WO | disclosed |
| EP-0563127-A1 | IMPROVED TREATMENT METHOD FOR CANCER. | UNIV MANITOBA (CA) | 1993-10-06 | — | — | EP | disclosed |
| WO-1992011035-A1 | IMPROVED TREATMENT METHOD FOR CANCER | UNIVERSITY OF MANITOBA (CA) | 1992-07-09 | — | — | WO | disclosed |